向EGFR激活以克服胆瘤癌中耐吉他的耐药性
Sonexai Kidoikhammouan1, Worachart Lert-Itthiporn2, Raksawan Deenonpoe3
1Biomedical Sciences Program, Graduate School, Khon Kaen University, Khon Kaen, Thailand.
Anticancer research
|December 3, 2024
概括
通过向EGFR,可以克服胆管癌 (CCA) 中的化疗耐药性. 这项研究发现,抑制EGFR可增强gemcitabine (Gem) 对抗Gem抗性CCA细胞的有效性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物耐药性 药物耐药性 药物耐药性
背景情况:
- 化疗耐药性是治疗胆管癌 (CCA) 的一个重大挑战,特别是对于那些无法接受手术的患者.
- 吉姆西塔 (Gem) 是一种关键的化疗剂,但耐药性限制了它的有效性.
- 识别和准与Gem耐药性相关的分子对于改善CCA治疗结果至关重要.
研究的目的:
- 为了研究胆管癌 (CCA) 胆管癌 (Gem) 耐药性的机制.
- 为了识别能够克服宝石抵抗力的分子目标.
- 评估准这些分子以增强Gem在CCA中的抗瘤作用的潜力.
主要方法:
- 通过逐步暴露于药物,建立了耐吉他的CCA细胞系 (CCA-GemR).
- 评估细胞特征,包括生长,交叉抵抗,细胞循环和殖民地形成.
- 利用酸化阵列和西部涂抹来识别分子机制,专注于EGFR.
- 分析了使用PanDrugs的潜在向疗法,并测试了与Gem结合使用的erlotinib.
主要成果:
- CCA-GemR细胞表现出较慢的生长和G1阶段细胞周期停止.
- 在所有CCA-GemR系中观察到对5-FU和西斯的交叉耐药性.
- 在CCA-GemR细胞中发现了表皮生长因子受体 (EGFR) 酸化的增加.
- 埃洛提尼布 (EGFR抑制剂) 协同增强了Gem的抗瘤活性,降低了Gem的抗性.
结论:
- 皮表皮生长因子受体 (EGFR) 是一个关键分子,参与了CCA中的Gem抗性.
- 用像erlotinib这样的抑制剂向EGFR可以克服Gem的耐药性.
- 抑制EGFR增强了Gem在CCA中的抗瘤功效,提供了一个潜在的治疗策略.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.2K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
